What is the recommended starting dose and formulation of methotrexate for a 54‑year‑old female with rheumatoid arthritis and normal liver function tests?

Starting Methotrexate for Rheumatoid Arthritis

Start with oral methotrexate at 15 mg once weekly, with a plan to escalate by 5 mg every 4-6 weeks up to 25-30 mg/week or the highest tolerable dose. 1

Initial Formulation

• Begin with oral methotrexate rather than subcutaneous administration for treatment initiation 1
• Oral administration is preferred despite moderate evidence suggesting superior efficacy of subcutaneous injections, due to ease of administration and similar bioavailability at typical starting doses 1
• The 2021 American College of Rheumatology guidelines conditionally recommend oral over subcutaneous methotrexate for patients initiating therapy 1

Starting Dose Strategy

The recommended starting dose is at least 15 mg/week, not lower doses like 7.5 mg/week 1

• Initiation/titration to a weekly dose of at least 15 mg within 4-6 weeks is conditionally recommended over starting at <15 mg 1
• Starting doses of 15 mg/week show a linear dose-response relationship with better efficacy compared to lower doses (7.5-10 mg/week) 1, 2
• The FDA label lists 7.5 mg weekly as a starting option, but current evidence supports higher initial dosing 3

Dose Escalation Plan

Escalate by 5 mg increments every 4-6 weeks if disease activity persists 1

• Target dose should be 25-30 mg/week or the highest tolerable dose 1
• Doses greater than 20 mg/week in adults are associated with increased incidence of serious toxic reactions, particularly bone marrow suppression, so careful monitoring is essential 3
• The recommendation refers only to initial prescribing and does not limit further dose escalation, which often provides additional efficacy 1

When to Switch to Subcutaneous Route

Consider switching to subcutaneous methotrexate if:

• Inadequate response to oral methotrexate at optimized doses 1
• Gastrointestinal side effects develop on oral therapy 1
• Poor compliance with oral administration 4, 5
• Doses exceed 20 mg/week (due to better bioavailability) 6, 4

Subcutaneous methotrexate shows statistically higher ACR20 response rates (85%) compared to oral (77%) in some studies 2

Monitoring Requirements for This Patient

Given her good liver function, establish baseline and ongoing monitoring 3, 5:

Before starting:

• Complete blood count 5
• Serum transaminases (already documented as normal) 5
• Serum creatinine with creatinine clearance calculation 5
• Chest radiograph 5
• Consider hepatitis B and C serologies 5

During treatment:

• Full blood count and serum transaminase/creatinine assays at least monthly for the first 3 months, then every 4-12 weeks 5
• More frequent monitoring (every 1-1.5 months) until stability is achieved 6

Folic Acid Supplementation

Prescribe folic acid 5 mg once weekly, taken at a different day from methotrexate 5

• Folate supplementation can be given routinely to reduce side effects 5
• Increased doses of folic/folinic acid are recommended strategies for patients not tolerating methotrexate 1

Common Pitfalls to Avoid

• Do not start too low: Starting at 7.5 mg/week is suboptimal; 15 mg/week provides better disease control with acceptable tolerability 1
• Do not escalate too slowly: Increase doses every 4-6 weeks rather than waiting months, as delayed escalation prolongs suboptimal disease control 1
• Do not switch to biologics prematurely: Maximize methotrexate optimization (dose and route) before concluding treatment failure 1, 2
• Do not use preserved formulations for high-dose or intrathecal use: Only preservative-free methotrexate should be used for these indications 3